BB Biotech Stock
BB Biotech AG
Company data
- Sector
- Financial Services
- Industry
- Financial - Conglomerates
- Country
- Switzerland
- CEO
- Daniel Koller
- Employees
- 10
- Market cap
- CHF2.7 B
- IPO
- 27/12/1993
BB Biotech AG is an investment fund overseen by Bellevue Asset Management AG. Headquartered in Kusnacht, Switzerland, the company is listed on the SIX Swiss Exchange and went public on December 27, 1993. With 10 employees under the leadership of CEO Daniel Koller, the firm allocates capital to publicly traded…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
BB Biotech stock: price history
1D
-2.7%
1W
-2.0%
1M
-6.9%
6M
+2.9%
YTD
+7.1%
1Y
+24.3%
2Y
+31.7%
5Y
-41.3%
10Y
-3.4%
Next earnings date
Next earnings date
23/10/2026 (in 6 days)
Volatility around earnings
~5% weaker price swings than usual
BB Biotech stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 16/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
BB Biotech AG is a specialized investment fund headquartered in Switzerland and supervised by Bellevue Asset Management AG. The fund focuses on targeted capital allocation in publicly listed companies worldwide operating in the field of modern biotechnology. A particular emphasis is placed on the development of new pharmaceuticals and diagnostic tools. The portfolio composition is based on a fundamental analysis approach to identify potential growth opportunities in this highly specialized sector.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Moderate
- Moat
- Narrow
- Moat type
- Network effects
- Capital intensity
- Low
- Customer concentration
- Unknown
Ask the agents about BB Biotech
BB Biotech stock metrics
P/E
1.97
P/B
0.86
EV/EBITDA
1.82
RETURN ON EQUITY
14.6%
NET MARGIN
410.0%
DEBT/EQUITY
0
DIVIDEND YIELD
4.7%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.5%
FLOAT SHARES
54,855,630
AVG. DAILY VOLUME (30D)
77,127
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about BB Biotech stock
What does BB Biotech do?
BB Biotech AG is a company in the Financial Services sector, Financial - Conglomerates industry, headquartered in Switzerland.
The CEO is Daniel Koller, the company employs around 10 people.
The IPO was on 27/12/1993; the stock trades on SIX under the ticker BION.SW.
When does BB Biotech report next?
The next earnings date is 23/10/2026.
Around past earnings, price swings were roughly -5% stronger than usual.
Does BB Biotech pay a dividend?
Yes. The last dividend was CHF 2.25 per share, ex-date 23/03/2026, paid on 25/03/2026.
The dividend yield is 4.7% (as of 30/06/2026).
Which stocks are comparable to BB Biotech?
Comparable stocks include Freedom Holding, Drugs Made In America Acquisition II, Art Technology Acquisition, UBS Group, Chubb, UBS Group, Julius Baer Gruppe and Luzerner Kantonalbank.
How can I get BB Biotech stock analyzed?
Clicking "Analyze stock" lets five strategies assess BB Biotech against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.